Review
Version 2
This version is not peer-reviewed
CANOMAD : A Multi-Faceted Disease
Version 1
: Received: 16 April 2020 / Approved: 17 April 2020 / Online: 17 April 2020 (15:15:12 CEST)
Version 2 : Received: 2 October 2020 / Approved: 5 October 2020 / Online: 5 October 2020 (11:07:50 CEST)
Version 2 : Received: 2 October 2020 / Approved: 5 October 2020 / Online: 5 October 2020 (11:07:50 CEST)
How to cite: Rickli, J.M.; Pomaleski, G.; Magno Gonçalves, M.V. CANOMAD : A Multi-Faceted Disease. Preprints 2020, 2020040303 Rickli, J.M.; Pomaleski, G.; Magno Gonçalves, M.V. CANOMAD : A Multi-Faceted Disease. Preprints 2020, 2020040303
Abstract
Objective: Elucidate the main clinical aspects of the CANOMAD spectrum. Methods: Bibliographical review trough databases (PubMed, Google Scholar, Orphanet, Oxford Academic) of articles from 1985 (1) to 2019 and later selection of the most applicable of the above, in order to construct a non-systematic review. Conclusion: CANOMAD is a chronic-ataxic autoimmune neuropathy associated with IgM monoclonal gammopathy. The correct diagnosis of this rare and multi-faceted disease will help optimal treatment.
Keywords
chronic-ataxic neuropathy; anti-disialosyl; IgM monoclonal gammopathy; CANOMAD
Subject
Medicine and Pharmacology, Neuroscience and Neurology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (1)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
Commenter: Júlia Rickli
Commenter's Conflict of Interests: Author